Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3461-3465

  Rabbani, Shafaat A ^a   Harakidas, Penelope ^a   Bowlin, Terry ^b   Attardo, Giorgio ^b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b Shire Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DIOXOLANE CYTIDINE; DOXORUBICIN; NUCLEOSIDE ANALOG; TROXACITABINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL DIVISION; CYTOSINE; DIOXOLANES; DOXORUBICIN; MALE; PROSTATIC NEOPLASMS; RATS;

EID: 0032146804     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Chiardo, A. National Cancer Institute roundtable on prostate cancer: future research directions. Cancer Res., 51: 2498-2505, 1991.
2. Franks, L. M. Etiology, epidemiology, and pathology of prostate cancer. Cancer (Phila.), 32: 1092-1095, 1993.
3. Palmberg, C., Koivisto, P., Hyytinen, E., Isola, J., Visakorpi, T., Kallioniemi, O. P., and Tammela, T. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur. Urol., 31: 216-219, 1997.
4. Fournier, G. Treatment of hormone-refractory prostate carcinoma. Eur. Urol., 30: 32-37, 1996.
5. Drees, M., Dengler, W. A., Roth, T., Labonte, H., Mayo, J., Malspeis, L., Grever, M., Sausville, E. A., and Fiebig, H. H. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res., 3: 273-279, 1997.
6. Isaacs, T. J., Isaacs, W. B., Feitz, W. J., and Scheres, J. Establishment and characterization of seven Dunning rat prostate cancer cell lines and their use in developing methods for predicting metastatic abilities of prostate cancer. Prostate, 9: 261-281, 1986.
7. Achbarou, A., Kaiser, S., Tremblay, G., Ste-Marie, L-G., Brodt, P., Goltzman, D., and Rabbani, S. A. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res., 54: 2372-2377, 1994.
8. Rabbani, S. A., Harakidas, P., Davidson, D. J., Henkin, J., and Mazar, A. P. Prevention of prostate cancer metastasis in vivo by a novel synthetic inhibitor of urokinase type plasminogen activator (uPA). Int. J. Cancer, 63: 840-845, 1996.
9. Batra, S., Karlsson, R., and Witt, L. Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells. Int. J. Cancer, 68: 644-649, 1996.
10. Bridges, E. G., and Cheng, Y-C. Use of novel β-L-nucleoside analogs for treatment and prevention of chronic hepatitis B virus and hepatocellular carcinoma. Prog. Liver Dis., 9: 231-245, 1995.
11. Larder, B. A., Kemp, S. D., and Harrigan, P. R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science (Washington DC), 269: 696-699, 1995.
12. Grove, K. L., and Yung-Chi, C. Uptake and metabolism of the new anticancer compound β-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res., 56: 4187-4191, 1996.
13. Rabbani, S. A., Gladu, J., Liu, B., and Goltzman, D. Regulation in vivo of the growth of Leydig cell tumors by antisense ribonucleic acid for parathyroid hormone-related peptide. Endocrinology, 136: 5416-5422, 1995.
14. Haq, M., Kremer, R., Goltzman, D., and Rabbani, S. A. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J. Clin. Invest., 91: 2416-2422, 1993.
15. Glantz, S. A. Primers of Biostatistics. New York: McGraw-Hill, 1981.
16. Steiner, M. S. Transforming growth factor-β and prostate cancer. World J. Urol., 13: 329-336, 1995.
17. Nannmark, U., Kitson, R. P., Johansson, B. R., Rivett, A. J., and Goldfarb, R. H. Immunocytochemical localization of multicatalytic protease complex (proteasome) during generation of murine IL-2-activated natural killer (A-NK) cells. Eur. J. Cell Biol., 71: 402-408, 1996.
18. Batra, S., Karlsson, R., and Witt, L. Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic cells. Int. J. Cancer, 68: 644-649, 1996.
19. Attardo, G., Smyth, J., Kadhim, S., Williams, P., Gourdeau, H., Lis, M., Dean, I., Angers, E., Clement, J., Quellet, M-C., Berryman, L., Harakidas, P., Rabbani, S. A., and Bowlin, T. L. Early preclinical studies with BCH-4556, an antineoplastic L-nucleoside. Proc. Am. Assoc. Cancer Res., 468, 1998.
20. Kadhim, S. A., Bowlin, T. L., Waud, W. R., Angers, E. G., Bibeau, L., DeMuys, J-M., Bednarski, K., Cimpoia, A., and Attardo, G. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (β-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res., 57: 4803-4810, 1997.
21. Cronauer, M. V., Klocker, H., Talasz, H., Geisen, F. H., Hobisch, A., Radmayr, C., Bock, G., Culig, Z., Schirmer, M., Reissigl, A., Bartsch, G., and Konwalinka, G. Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate, 28: 172-181, 1996.
22. Sagaster, P., Flamm, J., Micksche, M., Fritz, E., Donner, G., and Ludwig, H. Maximal androgen blockade in combination with methotrexate for treatment of metastatic prostate cancer. J. Cancer Res. Clin. Oncol., 122: 171-176, 1996.
23. Kreis, W., Budman, D. R., and Calabro, A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br. J. Urol., 79: 196-202, 1997.
24. Nagy, A., Armatis, P., Cai, R. Z., Szepeshazi, K., Halmos, G., and Schally, A. V. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxo-rubicin. Proc. Natl. Acad. Sci. USA, 94: 652-656, 1997.
25. Bos, S. D. An overview of current clinical experience with strontium-89 (Metastron). Prostate Suppl., 5: 23-26, 1994.